BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37891556)

  • 1. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease.
    Jiang W; Gan C; Zhou X; Yang Q; Chen D; Xiao H; Dai L; Chen Y; Wang M; Yang H; Li Q
    Cardiovasc Diabetol; 2023 Oct; 22(1):293. PubMed ID: 37891556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes.
    Nosadini R; Tonolo G
    Nutr Metab Cardiovasc Dis; 2011 Feb; 21(2):79-85. PubMed ID: 21186102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling.
    Chen X; Tan H; Xu J; Tian Y; Yuan Q; Zuo Y; Chen Q; Hong X; Fu H; Hou FF; Zhou L; Liu Y
    Kidney Int; 2022 Sep; 102(3):506-520. PubMed ID: 35644285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
    Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X
    Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
    Lay AC; Hale LJ; Stowell-Connolly H; Pope RJP; Nair V; Ju W; Marquez E; Rollason R; Hurcombe JA; Hayes B; Roberts T; Gillam L; Allington J; Nelson RG; Kretzler M; Holly JMP; Perks CM; McArdle CA; Welsh GI; Coward RJM
    Diabetologia; 2021 Jul; 64(7):1690-1702. PubMed ID: 33758952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
    Zuo F; Wang Y; Xu X; Ding R; Tang W; Sun Y; Wang X; Zhang Y; Wu J; Xie Y; Liu M; Wang Z; Yi F
    Metabolism; 2024 Jan; 150():155724. PubMed ID: 37952690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease.
    Hao Y; Fan Y; Feng J; Zhu Z; Luo Z; Hu H; Li W; Yang H; Ding G
    Cell Commun Signal; 2024 Jan; 22(1):26. PubMed ID: 38200543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5.
    Zhang Y; Xia S; Tian X; Yuan L; Gao Y; Liu D; Qi H; Wang S; Liu Z; Li Y; Zhao Z; Liu W
    FASEB J; 2024 May; 38(10):e23668. PubMed ID: 38742811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.
    Chen D; Liu Y; Chen J; Lin H; Guo H; Wu Y; Xu Y; Zhou Y; Zhou W; Lu R; Zhou J; Wu J
    Eur J Pharmacol; 2021 Jul; 902():174121. PubMed ID: 33901462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.
    Zhang Z; Liang W; Luo Q; Hu H; Yang K; Hu J; Chen Z; Zhu J; Feng J; Zhu Z; Chi Q; Ding G
    Front Endocrinol (Lausanne); 2021; 12():797025. PubMed ID: 35095764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
    Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
    J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-
    He J; Cui J; Shi Y; Wang T; Xin J; Li Y; Shan X; Zhu Z; Gao Y
    J Diabetes Res; 2023; 2023():7423661. PubMed ID: 37261217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects and mechanisms of total flavones of Abelmoschus manihot in inhibiting podocyte necroptosis and renal fibrosis in diabetic kidney disease].
    Chen JX; Fang QJ; Wan YG; Liu YL; Wang Y; Wu W; Tu Y; Wang MZ; Wang DG; Ge HT
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(15):4137-4146. PubMed ID: 37802782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
    Zheng D; Tao M; Liang X; Li Y; Jin J; He Q
    Histol Histopathol; 2020 Apr; 35(4):405-415. PubMed ID: 31650524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Klotho ameliorates oxidized low density lipoprotein (ox-LDL)-induced oxidative stress via regulating LOX-1 and PI3K/Akt/eNOS pathways.
    Yao Y; Wang Y; Zhang Y; Liu C
    Lipids Health Dis; 2017 Apr; 16(1):77. PubMed ID: 28407763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jiedu Tongluo Baoshen formula enhances podocyte autophagy and reduces proteinuria in diabetic kidney disease by inhibiting PI3K/Akt/mTOR signaling pathway.
    Jin D; Liu F; Yu M; Zhao Y; Yan G; Xue J; Sun Y; Zhao D; Li X; Qi W; Wang X
    J Ethnopharmacol; 2022 Jul; 293():115246. PubMed ID: 35398500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klotho inhibits PKCα/p66SHC-mediated podocyte injury in diabetic nephropathy.
    Jiang W; Xiao T; Han W; Xiong J; He T; Liu Y; Huang Y; Yang K; Bi X; Xu X; Yu Y; Li Y; Gu J; Zhang J; Huang Y; Zhang B; Zhao J
    Mol Cell Endocrinol; 2019 Aug; 494():110490. PubMed ID: 31207271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huangkui capsule in combination with metformin ameliorates diabetic nephropathy via the Klotho/TGF-β1/p38MAPK signaling pathway.
    Gu LY; Yun-Sun ; Tang HT; Xu ZX
    J Ethnopharmacol; 2021 Dec; 281():113548. PubMed ID: 33152427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paeoniflorin binds to VEGFR2 to restore autophagy and inhibit apoptosis for podocyte protection in diabetic kidney disease through PI3K-AKT signaling pathway.
    Wang X; Jiang L; Liu XQ; Huang YB; Wang AL; Zeng HX; Gao L; Zhu QJ; Xia LL; Wu YG
    Phytomedicine; 2022 Nov; 106():154400. PubMed ID: 36049428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.